Temozolomide in Combination With NF-κB Inhibitor Significantly Disrupts the Glioblastoma Multiforme Spheroid Formation
Glioblastoma multiforme (GBM) is the most common malignant primary brain tumor, accounting for 50% of all cases. GBM patients have a five-year survival rate of merely 5.6% and a median overall survival of 14.6 months with the “Stupp” regimen, 20.9 months w...
Saved in:
| Main Authors: | Hui Xia, Naze G. Avci, Yasemin Akay, Yoshua Esquenazi, Lisa H. Schmitt, Nitin Tandon, Jay-Jiguang Zhu, Metin Akay |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
IEEE
2020-01-01
|
| Series: | IEEE Open Journal of Engineering in Medicine and Biology |
| Subjects: | |
| Online Access: | https://ieeexplore.ieee.org/document/8945401/ |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Targeted Sensitization of Glioblastoma Multiforme Using AAAPT Technology
by: Megan Mendieta, et al.
Published: (2023-01-01) -
Kaposi’s sarcoma occurring in a glioblastoma multiforme on temozolomide
by: Jiong-Huang Lim, et al.
Published: (2025-01-01) -
Glioblastoma multiforme: an updated overview of temozolomide resistance mechanisms and strategies to overcome resistance
by: Jianlin Pu, et al.
Published: (2025-05-01) -
Precise processing of pure undiluted PEGDA via inkjet printing for drug release systems
by: Sannan Ahmed, et al.
Published: (2024-12-01) -
Prognostic Value of C-Reactive Protein to Albumin Ratio in Glioblastoma Multiforme Patients Treated with Concurrent Radiotherapy and Temozolomide
by: Erkan Topkan, et al.
Published: (2020-01-01)